Cytokeratin 14 Antibody (CL14565)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-26868
Key Product Details
Validated by
Orthogonal Validation
Species Reactivity
Human
Applications
Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG2B Clone # CL14565
Concentration
1 mg/ml
Product Specifications
Immunogen
This antibody was developed against a Synthetic Peptide of P02533. Actual immunogen sequence is proprietary.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Scientific Data Images for Cytokeratin 14 Antibody (CL14565)
Immunohistochemistry-Paraffin: Cytokeratin 14 Antibody (CL14565) [NBP3-26868]
Staining of human breast shows strong cytoplasmic positivity in basal layer of ductal cells.Immunohistochemistry-Paraffin: Cytokeratin 14 Antibody (CL14565) [NBP3-26868]
Staining of human skin shows strong cytoplasmic positivity in squamous epithelial cells.Applications for Cytokeratin 14 Antibody (CL14565)
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
2-10 ug/ml
Immunohistochemistry
1:5000 - 1:10000
Western Blot
1 ug/ml
Application Notes
ICC/IF Fixation Permeabilization: Use PFA/Triton X-100. For IHC-Paraffin, HIER pH 6 retrieval is recommended.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS, pH 7.2, 40% glycerol
Preservative
0.02% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Cytokeratin 14
Alternate Names
CK14, KRT14
Gene Symbol
KRT14
Additional Cytokeratin 14 Products
Product Documents for Cytokeratin 14 Antibody (CL14565)
Product Specific Notices for Cytokeratin 14 Antibody (CL14565)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...